Mentha Capital acquires majority stake in Pharmavize

7 September 2015

Mentha Capital has acquired a majority stake in Pharmavize, a niche pharmaceutical development service provider in Belgium. Pharmavize has been in the business for over 20 years, providing the highest possible standard of CMC development services to a broad customer base from emerging bio-tech to tier-one pharmaceutical companies.

Pharmavize is a contractor specialized in the development and manufacturing of early phase clinical supplies. It is also operating a well respected  regulatory & compliance consultancy department. Pharmavize is thoroughly familiar with European and American regulatory frameworks and guarantees compliance with all applicable guidelines and directives. The company is serving clients from all over the world, including Europe, the United States and Japan. The business has experienced strong growth over the past years. Management and employees are aiming to build further on this strong footing over the next few years through further organic growth as well as acquisitions.